AANEM News Express

AANEM News Express

Science News: Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series

2/3/2021
 
NSEB.jpgSubmitted by: Pritikanta Paul, MD
Edited by: Elliot Bodofsky, MD

Datta, et al. Retrospective analysis of eculizumab in patients with acetylcholine receptor antibody-negative myasthenia gravis: A case series. Journal of Neuromuscular Diseases. 2020;7:269-277.

Summary: Eculizumab has been approved and used for AChR antibody positive myasthenia gravis but little is known about its efficacy for AChR seronegative cases. In this small retrospective study (N=6), treatment outcome with eculizumab for AChR negative patients was assessed. Clinically meaningful reductions (≥2 points) in total MG-ADL scores were observed before or at five months and were maintained to month twelve in all patients. There was also a reduction in the mean number of exacerbations per patient, before and after eculizumab initiation, respectively and no treatment related adverse effects.

Comments: There is preliminary evidence of a potential beneficial role of eculizumab in treatment refractory seronegative myasthenia gravis warranting larger randomized trials.
 


View Related News Stories:

  EducationScience News NSEB


Recent AANEM News

Remembering George Kraft, MD, MS

The American Clinical Neurophysiology Society to Hold Another Townhall Meeting of Clinical Neurophysiology, Epilepsy, and Neuromuscular Fellowship Program Directors

Science News: Amyotrophic Lateral Sclerosis and Noninvasive Positive Pressure Ventilatory Support: "Nasal Noninvasive Ventilation" or "Noninvasive Ventilatory Support"?

CMS Finalizes Updates to Physician Fee Schedule

Advocacy in Action: State Liaison Leads the Way for Patient Advocacy in Washington and Beyond





Advertisement

ABEM

Advertisement

Donate

Advertisement